A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

NCT05810597 · Completed

Last updated 2026-05-28

This study is testing whether two versions of the diabetes medication tirzepatide, given by different injection devices, produce similar levels in the blood of healthy participants.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 65 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2023-04 · est. completion 2023-07

Where 3 sites · United States

What this study is testing ClinicalTrials.gov NCT05810597 ↗

Description as written by the study sponsor.

The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of tirzepatide and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 14 weeks, including screening.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Single Dose Pen Device

Used to administer tirzepatide SC
Multi-use Prefilled Pen Device

Used to administer tirzepatide SC

Main thing measured	Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tirzepatide
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05810597 ↗